Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1048

1.

Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease.

Panomvana D, Sripradit S, Angthararak S.

J Clin Rheumatol. 2008 Feb;14(1):6-11. doi: 10.1097/RHU.0b013e318164dceb.

PMID:
18431090
[PubMed - indexed for MEDLINE]
2.

Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level.

Stamp LK, Barclay ML, O'Donnell JL, Zhang M, Drake J, Frampton C, Chapman PT.

Clin Pharmacol Ther. 2011 Sep;90(3):392-8. doi: 10.1038/clpt.2011.113. Epub 2011 Jul 27.

PMID:
21796116
[PubMed - indexed for MEDLINE]
3.

The optimal use of allopurinol: an audit of allopurinol use in South Auckland.

Stamp L, Gow P, Sharples K, Raill B.

Aust N Z J Med. 2000 Oct;30(5):567-72.

PMID:
11108066
[PubMed - indexed for MEDLINE]
4.

[Usefulness of combination treatment using allopurinol and benzbromarone for gout and hyperuricemia accompanying renal dysfunction: kinetic analysis of oxypurinol].

Ohno I, Okabe H, Yamaguchi Y, Saikawa H, Uetake D, Hikita M, Gomi H, Ichida K, Hosoya T.

Nihon Jinzo Gakkai Shi. 2008;50(4):506-12. Japanese.

PMID:
18546882
[PubMed - indexed for MEDLINE]
5.

Relation between adverse events associated with allopurinol and renal function in patients with gout.

Vázquez-Mellado J, Morales EM, Pacheco-Tena C, Burgos-Vargas R.

Ann Rheum Dis. 2001 Oct;60(10):981-3.

PMID:
11557658
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events.

Dalbeth N, Stamp L.

Semin Dial. 2007 Sep-Oct;20(5):391-5.

PMID:
17897242
[PubMed - indexed for MEDLINE]
7.

Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout.

Dalbeth N, Kumar S, Stamp L, Gow P.

J Rheumatol. 2006 Aug;33(8):1646-50.

PMID:
16783857
[PubMed - indexed for MEDLINE]
8.

A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout.

Chao J, Terkeltaub R.

Curr Rheumatol Rep. 2009 Apr;11(2):135-40. Review.

PMID:
19296886
[PubMed - indexed for MEDLINE]
9.

An audit of a therapeutic drug monitoring service for allopurinol therapy.

Kannangara DR, Ramasamy SN, Ray JE, Jones G, Graham GG, Williams KM, Day RO.

Ther Drug Monit. 2013 Dec;35(6):863-6. doi: 10.1097/FTD.0b013e318299920a.

PMID:
24263644
[PubMed - indexed for MEDLINE]
10.

Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.

Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N.

Arthritis Rheum. 2008 Nov 15;59(11):1540-8. doi: 10.1002/art.24209.

PMID:
18975369
[PubMed - indexed for MEDLINE]
Free Article
11.

Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout.

Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, Herrero-Beites A, García-Erauskin G, Ruiz-Lucea E.

Ann Rheum Dis. 1998 Sep;57(9):545-9.

PMID:
9849314
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Furosemide increases plasma oxypurinol without lowering serum urate--a complex drug interaction: implications for clinical practice.

Stamp LK, Barclay ML, O'Donnell JL, Zhang M, Drake J, Frampton C, Chapman PT.

Rheumatology (Oxford). 2012 Sep;51(9):1670-6. doi: 10.1093/rheumatology/kes091. Epub 2012 Apr 26.

PMID:
22539486
[PubMed - indexed for MEDLINE]
Free Article
13.

Allopurinol dosage selection: relationships between dose and plasma oxipurinol and urate concentrations and urinary urate excretion.

Day RO, Miners JO, Birkett DJ, Whitehead A, Naidoo D, Hayes J, Savdie E.

Br J Clin Pharmacol. 1988 Oct;26(4):423-8.

PMID:
3190992
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Improvement of renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts.

Perez-Ruiz F, Calabozo M, Herrero-Beites AM, García-Erauskin G, Pijoan JI.

Nephron. 2000 Nov;86(3):287-91.

PMID:
11096285
[PubMed - indexed for MEDLINE]
15.

Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout.

Feher MD, Hepburn AL, Hogarth MB, Ball SG, Kaye SA.

Rheumatology (Oxford). 2003 Feb;42(2):321-5.

PMID:
12595630
[PubMed - indexed for MEDLINE]
Free Article
16.

Improving the use of allopurinol in chronic gout: monitoring oxypurinol levels to guide therapy.

Keith MP, Gilliland WR.

Clin Pharmacol Ther. 2011 Sep;90(3):363-4. doi: 10.1038/clpt.2011.146.

PMID:
21862966
[PubMed - indexed for MEDLINE]
17.

[A study of serum oxipurinol concentration and renal function in patients administered allopurinol].

Saji M.

Nihon Jinzo Gakkai Shi. 1996 Dec;38(12):640-50. Japanese.

PMID:
9014485
[PubMed - indexed for MEDLINE]
18.

Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output.

Perez-Ruiz F, Calabozo M, Erauskin GG, Ruibal A, Herrero-Beites AM.

Arthritis Rheum. 2002 Dec 15;47(6):610-3.

PMID:
12522834
[PubMed - indexed for MEDLINE]
Free Article
19.

An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.

Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y.

J Clin Rheumatol. 2011 Jun;17(4 Suppl 2):S13-8. doi: 10.1097/RHU.0b013e31821d36cc.

PMID:
21654265
[PubMed - indexed for MEDLINE]
20.

Does benzbromarone in therapeutic doses raise renal excretion of oxipurinol?

Mertz DP, Eichhorn R.

Klin Wochenschr. 1984 Dec 17;62(24):1170-2.

PMID:
6530890
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk